In this article
The Ibero-American consensus on reactive arthritis, published by M. Benegas and colleagues in Clinical Rheumatology on September 5, 2026, sets out 13 overarching principles and 54 recommendations on the definition, diagnosis and management of reactive arthritis (ReA), including 17 recommendations on the diagnostic process.[7] Its treatment algorithm depends on whether disease is peripheral, predominantly axial or entheseal, and it recommends a conventional synthetic DMARD, preferably sulfasalazine, when NSAIDs or corticosteroids have not controlled the arthritis.[7]
Reactive arthritis is inflammatory arthritis that follows an infection, commonly in the digestive or genitourinary tract.[1] Joint symptoms can begin after the infection has cleared; knees, ankles and tendon attachment sites are among the areas involved.[1]
Sources checked October 25, 2026; the 2026 Ibero-American consensus and the 1999 Berlin workshop report were added November 5, 2026. This is a descriptive guide, not a diagnosis or a treatment recommendation.
Key takeaways
- The 2026 Ibero-American consensus on reactive arthritis (Benegas et al., Clinical Rheumatology) agreed 13 overarching principles and 54 recommendations, each with at least 70 percent expert agreement.
- According to NIAMS, reactive arthritis symptoms usually begin one to six weeks after an infection, with Chlamydia, Salmonella, Shigella, Campylobacter and Yersinia among the named triggers.
- NIAMS states there is no single test for reactive arthritis; an HLA-B27 result on its own neither establishes nor excludes the diagnosis.
- The consensus panel agreed unanimously (100 percent) on using a csDMARD after NSAIDs or corticosteroids fail, and 91 percent agreed that sulfasalazine is the preferred csDMARD.
- Carter et al. (2010) reported 17 of 27 responders on combination antibiotics versus 3 of 15 on placebo in chronic Chlamydia-associated ReA; Kuuliala et al. (2013) found no significant difference in recent-onset ReA.
- The NHS describes a usual course of up to six months, with some cases lasting longer or coming back.
What does reactive arthritis mean?
The American College of Rheumatology describes reactive arthritis as a spondyloarthropathy, a category of inflammatory joint disease.[3] Older records may use the name Reiter's syndrome.[3]
NIAMS names Chlamydia, Salmonella, Shigella, Campylobacter and Yersinia among the bacterial triggers.[1] An infection history can involve the digestive tract rather than a sexually transmitted infection.[1]
Reactive arthritis, abbreviated ReA, belongs to the spondyloarthritis (SpA) family with ankylosing spondylitis, psoriatic arthritis and arthritis linked to bowel disease such as Crohn's disease, which is why HLA-B27 comes up in testing.
A definition has been debated for decades. The 1999 Berlin workshop report by Braun and colleagues (2000) reserved the term for HLA-B27 and spondyloarthritis associated presentations, set six months as the line between acute and chronic ReA, and described an asymmetrical, mainly leg-joint pattern, unlike the symmetrical small-joint pattern of rheumatoid arthritis.[8]
What does the Ibero-American consensus on reactive arthritis recommend?
The Ibero-American consensus on reactive arthritis: definition, diagnosis, and management is a set of 13 overarching principles and 54 recommendations published in Clinical Rheumatology (volume 45, pages 6377 to 6391) on September 5, 2026.[7] M. Benegas, N. Zamora, M. V. Martire and colleagues wrote it because ReA varies widely between patients, lacks universally accepted diagnostic criteria and has scarce evidence-based treatment guidance.[7]
How was the consensus developed?
A multidisciplinary panel ran a PRISMA systematic review of MEDLINE, LILACS, Cochrane and EULAR, ACR, PANLAR and SAR conference abstracts. Treatment questions used PICO and GRADE, definitions were agreed by Delphi rounds, and every recommendation needed at least 70 percent agreement.[7]
What does it say about definition and diagnosis?
The panel included 17 specific recommendations on the diagnostic process and describes the document as the first regional consensus to standardize definitions, classification criteria and treatment algorithms for ReA.[7] The abstract does not list each recommendation; the full text is on Springer (DOI 10.1007/s10067-026-08400-8).
How does the consensus organize treatment?
The consensus sets a treatment algorithm according to whether involvement is peripheral (joints of the arms and legs), predominantly axial (the spine and sacroiliac joints) or entheseal (where tendons and ligaments attach to bone).[7] It also covers features outside the joints, such as eye inflammation.[7]
Several treatment recommendations reached moderate certainty of evidence, a strong grade and high agreement. These include using a conventional synthetic disease-modifying antirheumatic drug (csDMARD) after NSAIDs and/or corticosteroids have failed, agreed by 100 percent of the panel, and choosing sulfasalazine as the preferred csDMARD, agreed by 91 percent.[7]
Sulfasalazine is a long-established csDMARD also used in rheumatoid arthritis treatment. A rheumatologist weighs the recommendation against the individual case and the blood test monitoring csDMARDs usually require.
| Element | What the abstract states |
|---|---|
| Authors and journal | M. Benegas, N. Zamora, M. V. Martire and colleagues published it in Clinical Rheumatology, volume 45, issue 11, in 2026. |
| Agreement threshold | Each recommendation required at least 70 percent agreement. |
| Output | The panel agreed 13 overarching principles and 54 recommendations, 17 of them on diagnosis. |
| Highest-agreement medicine recommendations | A csDMARD after NSAID or corticosteroid failure reached 100 percent agreement, and sulfasalazine as the preferred csDMARD reached 91 percent. |
What are the limits of the consensus?
The authors state that evidence for ReA treatment is limited, and only some recommendations reached moderate certainty.[7] A consensus is structured expert agreement built on a literature review, not a new randomized trial. It was written for rheumatology practice across Ibero-America rather than as a US guideline, so US readers can bring it to a rheumatologist as context alongside NIAMS and American College of Rheumatology information.
What symptoms and timing do medical sources describe?
NIAMS describes symptoms beginning one to six weeks after an infection.[1] Its symptom list includes joint swelling or stiffness, heel pain, urinary symptoms and eye inflammation.[1] Not everyone has the joint, urinary and eye features together.[1]
The NHS lists sudden severe pain and swelling in one joint, joint symptoms with fever, and joint symptoms with eye pain or vision problems among reasons for urgent medical assessment.[4] Seek urgent medical care for these symptoms rather than using a directory to identify the cause.[4]
Heel pain in ReA often reflects enthesitis, inflammation where a tendon attaches to bone, which the 2026 Ibero-American consensus treats as its own branch of care.[7] Heel pain also has mechanical causes, covered on our plantar fasciitis condition page.
Is there a test for reactive arthritis?
NIAMS says there is no single diagnostic test.[2] Clinicians combine the history and examination with tests selected to investigate infection, inflammation and other possible causes of joint symptoms.[2]
| Test or assessment | What it contributes | What it does not settle |
|---|---|---|
| HLA-B27 blood test | Identifies a genetic marker.[2] | A positive or negative result alone does not establish or exclude reactive arthritis.[2] |
| Stool or urine culture | Looks for a preceding bacterial infection.[2] | A negative result may follow clearance of the infection.[2] |
| Joint-fluid analysis | Investigates inflammation and alternatives such as joint infection or gout.[2] | It is part of the evaluation, not a self-diagnosis shortcut.[2] |
| CRP or sedimentation rate | Measures inflammation.[2] | Neither marker is specific to reactive arthritis.[2] |
Septic arthritis, a joint infection that needs prompt treatment, is one alternative that joint-fluid analysis helps exclude; our overview of pyogenic arthritis explains that condition. Psoriatic arthritis is another spondyloarthritis that can affect heels, toes and the spine, and the post on psoriatic arthritis symptoms describes how it presents.
Who evaluates reactive arthritis and what care is discussed?
The NHS describes referral to a rheumatologist for assessment and care.[4] An ophthalmologist or dermatologist may also be involved when eye or skin symptoms are present.[4]
The American College of Rheumatology names NSAIDs, corticosteroids and disease-modifying antirheumatic drugs in its treatment overview.[3] It also discusses biologic medicines in selected clinical circumstances.[3] These are categories to discuss with the treating clinician, not a ranking or a medication plan for the reader.
NIAMS separately describes antibiotics when a current bacterial infection is documented.[2] The trial summaries below concern arthritis outcomes, rather than instructions for treating an infection.
A primary care physician often orders the first tests, and an infectious disease or sexual health clinician may treat a documented infection. The arthritis treatment guide covers therapies used across joint disease, and the arthritis condition page explains how the main types differ.
What did the chronic Chlamydia-associated trial measure?
Carter and colleagues' 2010 randomized, double-blind trial enrolled people with chronic reactive arthritis who tested positive for Chlamydia trachomatis or Chlamydia pneumoniae by PCR.[5] The study followed participants for nine months and compared six months of combination antibiotics with placebo.[5] Results pooled two combinations: doxycycline with rifampin and azithromycin with rifampin.[5]
The month-six primary endpoint required at least 20 percent improvement from baseline in at least four of six measures, without worsening in any measure.[5] It was reached by 17 of 27 participants receiving combination antibiotics and 3 of 15 receiving placebo.[5]
This is a result from a selected PCR-positive chronic-disease population. It does not establish an antibiotic plan for every person with joint pain after an infection. This summary uses the authors' abstract, not an independent reanalysis of patient records.[5]
What did the recent-onset trial measure?
Kuuliala and colleagues' 2013 randomized, double-blind trial studied 56 people with recent-onset reactive arthritis: 47 had an intestinal-infection-associated presentation and nine a urinary-infection-associated presentation.[6] Participants received three months of ofloxacin plus roxithromycin or placebo and were assessed through six months.[6]
At six months, the authors reported recovery from arthritis in 20 of 26 participants assigned antibiotics and 20 of 30 assigned placebo.[6] The reported comparison was not statistically significant, with p = 0.55.[6]
This trial and the chronic Chlamydia-associated trial asked different questions in different populations. Their enrollment rules, medicines and outcome definitions should remain visible when discussing the findings. These are two selected original trials, not a systematic review or a treatment verdict.[5][6]
Both trials are cited by the 2026 Ibero-American consensus on reactive arthritis, so neither trial alone represents the panel's view.[7]
What should you bring to a rheumatology appointment?
Prepare a dated account of the infection, when joint symptoms began, any eye or urinary symptoms, and the test results already obtained. NIAMS describes those histories and examinations as part of the diagnostic process.[2]
Questions to bring: What alternatives are still being investigated? Is there evidence of a current infection? Which specialist will coordinate joint and eye concerns? What does each proposed test answer? Ask the clinician to explain the purpose of a proposed medicine rather than choosing one from a research summary.
- The date and type of the preceding infection and any test that confirmed it.
- When each joint, heel, back, eye or skin symptom started.
- Results already obtained, such as stool or urine cultures, HLA-B27, CRP, sedimentation rate or joint-fluid analysis.
- Each medicine tried for the joints, with dose, duration and effect.
If NSAIDs or a corticosteroid have not controlled the arthritis, ask how the consensus csDMARD recommendation applies to you.[7]
How can you compare directory profiles without assuming expertise?
In Regenerated.com's September 2026 export of 9,042 published clinic records, 2,791 carried the Arthritis Treatment label across all 50 states plus Washington, DC. Source: our clinic-directory snapshot. This measures directory coverage, not market size, rheumatologist supply or confirmed reactive arthritis services.
The Arthritis Treatment clinic directory provides the broader category. Two profiles linked from that category when checked are Portland Clinic of Holistic Health in Portland, Oregon and Regenexx in Des Moines, Iowa. These links are examples of directory records to inspect, not recommendations for reactive arthritis care.
Before contacting a listed clinic, check the recorded address and services, then ask whether it evaluates reactive arthritis, whether a rheumatologist is involved, and where it refers concerns outside its scope. The category label does not answer those questions. Do not infer that an injection or regenerative service listed on a profile is appropriate for this diagnosis.
Regenerated.com is free for patients. Listing order is not a paid ranking, Featured slots are labeled and capped, and Verified means a clinic completed credential checks, not that it spent more. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified and organic listings explains each label. State lists such as arthritis treatment clinics in Florida narrow the search once a rheumatologist has confirmed the diagnosis.
Frequently asked questions
Is reactive arthritis the same as Reiter's syndrome?
Yes. Reiter's syndrome is an older name used for reactive arthritis, according to the American College of Rheumatology.[3] Clinicians now use reactive arthritis or ReA, though the older label still appears in past records. A historical label does not replace a current clinical assessment by a rheumatologist.
Do all three joint, eye and urinary symptoms have to occur?
No. NIAMS states that not everyone experiences all three features and they may not occur together.[1] Many people notice joint swelling or heel pain on its own. A symptom checklist cannot establish the diagnosis; a clinician combines the history, examination and selected tests.
How long does reactive arthritis last?
The NHS describes a usual course of up to six months while noting that some cases last longer or recur.[4] The 1999 Berlin workshop report by Braun and colleagues proposed six months as the cutoff between acute and chronic reactive arthritis.[8] That general description is not a forecast for an individual. Arthritis that persists is a reason to ask a rheumatologist about disease-modifying medicines.
Does an Arthritis Treatment listing confirm reactive arthritis care?
No. Our category records a broad service label. Confirm reactive arthritis assessment, clinician specialty and referral arrangements directly with the clinic; the listing is not evidence of condition-specific expertise. Listing order on Regenerated.com is not a paid ranking, Featured slots are labeled and capped, and Verified means credential checks rather than spend. The directory is free for patients, and inclusion is not an endorsement of any clinic.
What is the Ibero-American consensus on reactive arthritis?
The Ibero-American consensus on reactive arthritis is a 2026 set of clinical recommendations by M. Benegas and colleagues, published in Clinical Rheumatology.[7] A multidisciplinary panel used a systematic review, GRADE methodology and a Delphi process to agree 13 overarching principles and 54 recommendations, each needing at least 70 percent agreement. It covers definitions, 17 diagnostic recommendations and a treatment algorithm for peripheral, predominantly axial and entheseal disease.
Do antibiotics treat reactive arthritis?
Antibiotics treat a documented current bacterial infection, according to NIAMS, but their role for the arthritis itself is narrower.[2] In Carter and colleagues' 2010 trial of PCR-positive chronic Chlamydia-associated disease, 17 of 27 people on combination antibiotics met the primary endpoint versus 3 of 15 on placebo.[5] In Kuuliala and colleagues' 2013 recent-onset trial, recovery did not differ significantly.[6] Ask your clinician which situation applies.
Sources
- NIAMS: Reactive Arthritis, reviewed May 2024. Checked October 25, 2026.
- NIAMS: Reactive Arthritis Diagnosis and Treatment, reviewed May 2024. Checked October 25, 2026.
- American College of Rheumatology: Reactive Arthritis, updated February 2025. Checked October 25, 2026.
- NHS: Reactive arthritis, reviewed December 16, 2024. Checked October 25, 2026.
- Carter et al., 2010: Combination antibiotics in chronic Chlamydia-induced reactive arthritis. Checked October 25, 2026.
- Kuuliala et al., 2013: Ofloxacin and roxithromycin in recent-onset reactive arthritis. Checked October 25, 2026.
- Benegas et al., 2026: Ibero-American consensus on reactive arthritis: definition, diagnosis, and management. Clinical Rheumatology 45(11):6377 to 6391. Checked November 5, 2026.
- Braun et al., 2000: On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis (4th International Workshop on Reactive Arthritis, Berlin, 1999). Checked November 5, 2026.